Next-Generation Japanese GLP-1 weight loss pills: Seeking North American Distributors
A carbonated granule supplement based on advanced Japanese immune research and a science-based approach to prevent over-eating enters the expanding U.S. weight loss market. Japan, 12th Mar 2026 – Asa Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; CEO: Tomoko Iwase), a manufacturer and distributor of health foods, has launched North American expansion of a next-generation diet supplement utilizing proprietary carbonated granule technology, targeting the rapidly growing global “GLP-1 (appetite-suppressing hormone)” support market. In conjunction with this launch, the company has formally begun inviting applications from strategic partners (distributors), including clinics,…
Read More